On Wednesday, in the course of current trade, Shares of Halcón Resources Corporation (NYSE:HK), dropped -1.91%, and is now trading at $1.29, as oil fell nearly 2 percent on Wednesday as traders and investors ignored a fifth straight weekly decline in U.S. crude stockpiles to focus instead on a big build in distillates, counting diesel, as the peak season for U.S. road travel got under way.
U.S. crude inventories fell 1.95 million barrels last week, more than the 1.7 million forecast by analysts in a Reuters poll, a report from the government-run Energy Information Administration showed.
Crude stocks at the Cushing, Oklahoma, delivery hub for U.S. oil also fell, together with gasoline stocks. Reuters Reports.
Halcón Resources Corporation, an independent energy company, is engaged in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States.
During an Afternoon trade, Shares of Southwestern Energy Co. (NYSE:SWN), dipped -0.72%, and is now trading at $24.99, as oil prices maintained losses Wednesday after weekly U.S. inventory data showed that crude stockpiles shrank but production rose to a new record.
Light, sweet crude for July delivery recently fell 91 cents, or 1.5%, to $60.35 a barrel on the New York Mercantile Exchange. Brent, the global benchmark, fell $1.27, or 1.9%, to $64.22 a barrel on ICE Futures Europe, according to WSJ.
Southwestern Energy Company, an independent energy company, engages in the exploration, development, and production of natural gas and oil in the United States. The company operates in two segments, Exploration, Development and Production; and Midstream Services.
Shares of Kinross Gold Corporation (NYSE:KGC), during its Wednesday’s current trading session fell -1.68%, and is now trading at $2.34.
Kinross Gold Corporation, declared that mining and crushing operations at its Maricunga mine resumed earlier this month, ahead of the anticipated June restart target. Operations were partially suspended on March 25 following an extreme weather event in northern Chile, which caused heavy damage to local infrastructure. The ADR plant operated throughout the restart effort, producing gold from existing material in the heap leach.
The Company would like to recognize the dedication and determination of its team in Chile in successfully restarting operations earlier than anticipated and in challenging conditions. An additional backup power plant has been installed to support the return to full operation, with main power lines predictable to be back in operation in September.
The temporary suspension of mining and crushing will have an impact on production and costs at Maricunga, particularly in the third quarter. However, as noted in the Company’s Q1 2015 news release, Kinross anticipates no change to its Company-wide or regional production guidance.
Kinross Gold Corporation, together with its auxiliaries, engages in the acquisition, exploration, and development of gold bearing properties. It is involved in mining and processing gold and silver ores. The company’s gold production and exploration activities are carried out principally in Canada, the United States, the Russian Federation, Brazil, Chile, Ghana, and Mauritania.
Finally, Sanofi (NYSE:SNY), gained 2.60% Wednesday.
Sanofi, declared that it has reached agreement with NHS England that cabazitaxel will once more be accessible on the NHS to clinically eligible men with advanced prostate cancer. Cabazitaxel was de-listed from the Cancer Drugs Fund (CDF) by NHS England on 12th March[1], however in order to support access to cabazitaxel during the transition period to a formal NICE appraisal outcome, Sanofi and NHS England have come to a contract that will enable provision of cabazitaxel to patients in England.
NICE has agreed to review the Technology Appraisal for cabazitaxel and we expect a result in 2016. Sanofi has presented a Patient Access Scheme as part of the re-appraisal of cabazitaxel by NICE. Sanofi also plans to re-submit cabazitaxel to the Scottish Medicines Consortium in 2015 to allow patients in Scotland access to this important medicine.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
